Journal profile · Hematology
Best Practice & Research Clinical Haematology
ISSN 1521-6926 · eISSN 1532-1924 · Elsevier BV · ENGLAND · Quarterly
Best Practice & Research Clinical Haematology: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 3.44; hybrid open access; APC about USD 3,730; median 48 days to acceptance (30 articles, last 24 months); community-reported acceptance: fairly easy; 31 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Best Practice & Research Clinical Haematology is published by Elsevier BV and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation and Lymphoma Diagnosis and Treatment, together about 32.6% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Best Practice & Research Clinical Haematology provides a comprehensive review of current clinical practice and thinking within the specialty of haematology.All chapters are commissioned and written by an international team of practicing clinicians with the Guest Editors for each issue drawn from a pool of renowned experts and opinion leaders.All chapters take the form of practical, evidence-based reviews that seek to address key clinical issues of diagnosis, treatment and patient management.Each issue follows a problem-orientated approach that focuses on the key questions to be addressed, clearly defining what is known and not known. Management will be described in practical terms so that it can be applied to the individual patient.Boxed and bulleted Learning Objectives and Practice Points are features within each chapter and will highlight the core and essential knowledge that will help the physician to provide the best care to their patients.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief R. P. GalePublisher website
Editorial board by country: none in mainland China; most named United States 4, United Kingdom 4, Italy 3, Switzerland 2 (13 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Acute Myeloid Leukemia ResearchMedicine13.8%
- Hematopoietic Stem Cell TransplantationMedicine10.2%
- Lymphoma Diagnosis and TreatmentMedicine8.6%
- Chronic Lymphocytic Leukemia ResearchMedicine7.3%
- Acute Lymphoblastic Leukemia researchMedicine7.2%
- Chronic Myeloid Leukemia TreatmentsMedicine5.1%
- CAR-T cell therapy researchMedicine4.2%
- Myeloproliferative Neoplasms: Diagnosis and TreatmentMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.44LetPub ·
- Impact factor (publisher)
- 3.4Publisher website ·
- CiteScore 2026-06
- 4.8LetPub ·
- CiteScore (publisher)
- 4.8Publisher website ·
- SJR 2026-06
- 0.95LetPub ·
- SNIP 2026-06
- 0.84LetPub ·
- h-index
- 70LetPub ·
- h-index
- 89OpenAlex ·
- i10-index
- 877OpenAlex ·
- 2-year mean citedness
- 4.59OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 27.27%LetPub ·
Volume
- Articles per year
- 30LetPub ·
Articles by year OpenAlex count · 1,547 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2025 | 31 | 11 | 68 |
| 2024 | 39 | 20 | 253 |
| 2023 | 57 | 20 | 440 |
| 2022 | 48 | 22 | 418 |
| 2021 | 60 | 9 | 620 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
48 daysMedian, submission to acceptance · P25–P75 28 days – 139 days
- Acceptance to online
- median 2 days (30 articles)
- Submission to online
- median 55 days
- Sample
- 30 articles with submission and acceptance dates (35 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 45 daysPublisher website ·
- First decision after review
- 61 daysPublisher website ·
- Submission to acceptance
- 49 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,730 / EUR 3,490 / GBP 2,990 / JPY 462,630 | — | — | |
| Publisher website | USD 3,600 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare8 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- First submission
- Free format: the journal's layout is not required
- Suggested reviewers
- Required
- Highlights
- Required
- Graphical abstract
- Required
- Cover letter
- Required
Article types accepted1
- clinical trial resultsClinical trial resultsIn line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the s…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Jurisdictional claims: neutral position on territorial disputes Model summary
Elsevier respects the decisions taken by its authors as to how they choose to designate territories and identify their affiliations in their published content. Elsevier’s policy is to take a neutral position with respect to territorial disputes or jurisdictional claims, including, but not limited to, maps and institutional affiliations.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Peer review process: single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed, does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier BV
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Quarterly
- ISSN
- 1521-6926
- Electronic ISSN
- 1532-1924
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Best Practice & Research Clinical Haematology
What CAS zone is Best Practice & Research Clinical Haematology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Best Practice & Research Clinical Haematology is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Best Practice & Research Clinical Haematology?
The latest impact factor listed by LetPub is 3.44; CiteScore 4.8, h-index 89.
How long does peer review take at Best Practice & Research Clinical Haematology?
Based on the dates recorded on 30 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 48 days (interquartile range 28–139 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Best Practice & Research Clinical Haematology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; First submission: Free format: the journal's layout is not required; Suggested reviewers: Required; Highlights: Required; Graphical abstract: Required; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Best Practice & Research Clinical Haematology based?
Of the 13 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (4), United Kingdom (4) and Italy (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Best Practice & Research Clinical Haematology?
According to LetPub and DOAJ records, Best Practice & Research Clinical Haematology is indexed in SCIE and Scopus.
Is Best Practice & Research Clinical Haematology open access, and what is the APC?
Best Practice & Research Clinical Haematology is a hybrid journal. For open-access publication: APC about USD 3,730.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .